Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 22
4 133
3 152
2 52
1 25
NEB 4
Curative setting
A 54
C 2
NEB 4
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 4
Breast Cancer 37
Endocrine Tumours 21
Gastrointestinal Cancers 73
Genitourinary Cancers 70
Gynaecological Malignancies 38
Head and neck cancer 12
Non-cancerous soft-tissue tumour 1
Sarcoma 12
Skin Cancers 29
Thoracic Malignancies 84
TMB-H solid tumours 1
Tumour agnostic 6
Curative setting
Brain Tumours 2
Breast Cancer 9
Endocrine Tumours 0
Gastrointestinal Cancers 16
Genitourinary Cancers 3
Gynaecological Malignancies 1
Head and neck cancer 1
Non-cancerous soft-tissue tumour 0
Sarcoma 3
Skin Cancers 14
Thoracic Malignancies 11
TMB-H solid tumours 0
Tumour agnostic 0

The ESMO-MCBS Scorecards

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Therapeutic Indication Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Olaparib - Placebo Maintenance therapy in patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to platinum-based ChT SOLO-2
    Gynaecological Malignancies
    		 Ovarian, fallopian tubes and peritoneum cancer BRCA-mut SOLO-2

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Trifluridine/Tipiracil (TAS-102) - Placebo Metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, in patients who have been previously treated with ≥2 prior systemic treatment regimens for advanced disease TAGS
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction adenocarcinoma - TAGS

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Pembrolizumab Axitinib Sunitinib First-line treatment of advanced RCC in adults KEYNOTE-426
    Genitourinary Cancers
    		 Renal cell cancer - KEYNOTE-426

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Avelumab Axitinib Sunitinib First-line treatment of adult patients with advanced RCC JAVELIN Renal 101
    Genitourinary Cancers
    		 Renal cell cancer - JAVELIN Renal 101

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Lanreotide - Placebo Grade 1 and a subset of grade 2 (Ki67 index up to 10%) GEP-NETs of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease CLARINET
    Endocrine Tumours
    		 Neuroendocrine Tumour - Entero-pancreatic Ki67 index up t o 10% CLARINET

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Everolimus Best supportive care Placebo Unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease RADIANT 3
    Endocrine Tumours
    		 Neuroendocrine Tumour - Pancreatic - RADIANT 3

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Octreotide - Placebo Treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded PROMID
    Endocrine Tumours
    		 Neuroendocrine Tumour - Midgut - PROMID

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Sunitinib - Placebo Treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours with disease progression in adults
    Endocrine Tumours
    		 Neuroendocrine Tumour - Pancreatic - -

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    177Lu-DOTATATE Best supportive care + octreotide Octreotide Unresectable or metastatic, progressive, well-differentiated (Grade 1 and Grade 2), somatostatin receptor positive-GEP-NETs in adults NETTER-1
    Endocrine Tumours
    		 Neuroendocrine Tumour - Midgut - NETTER-1

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Brigatinib - Single arm Monotherapy for the treatment of adult patients with anaplastic lymphoma kinase ALK positive advanced NSCLC previously treated with crizotinib ALTA
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer ALK+ ALTA

    4

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      4
    Pembrolizumab Carboplatin + either paclitaxel or nab-paclitaxel Placebo + carboplatin + either paclitaxel or nab-paclitaxel First-line metastatic squamous non-small cell lung cancer KEYNOTE-407
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer - KEYNOTE-407

    A

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a/F1
      4

      A
    Atezolizumab Bevacizumab, paclitaxel and carboplatin Bevacizumab, paclitaxel and carboplatin In combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC) IMpower150
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer - IMpower150

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Atezolizumab Bevacizumab, paclitaxel and carboplatin Bevacizumab, paclitaxel and carboplatin In patients with EGFR mutant or ALK-positive NSCLC, atezolizumab, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies IMpower150
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ or ALK-positive IMpower150

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Atezolizumab Carboplatin plus nab-paclitaxel Carboplatin plus nab-paclitaxel In combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLC IMpower130
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer - IMpower130

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Ribociclib Endocrine therapy Placebo + endocrine therapy Treatment of women with HR+, HER2 negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.. In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone‑releasing hormone (LHRH) agonist. MONALEESA-7
    Breast Cancer
    		 Breast Cancer HR+ HER2- MONALEESA-7

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      5
    Abemaciclib Aromatase inhibitor Placebo + aromatase inhibitor EMA: First-line treatment of hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer. FDA: Abemaciclib in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer MONARCH 3
    Breast Cancer
    		 Breast Cancer HR+, HER2- MONARCH 3

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Abemaciclib Fulvestrant Fulvestrant + placebo Treatment of women with hormone receptor-positive, HER2-negative locally advanced or MBC as initial endocrine-based therapy, or in women who have received prior ET MONARCH 2
    Breast Cancer
    		 Breast Cancer HR+ HER2- MONARCH 2

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Ribociclib Fulvestrant Placebo + fulvestrant Treatment of women with hormone receptor-positive, HER2-negative locally advanced or MBC as initial endocrine-based therapy, or in women who have received prior ET MONALEESA-3
    Breast Cancer
    		 Breast Cancer HR+ HER2- MONALEESA-3

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Fulvestrant - Anastrozole Treatment of estrogen receptor positive (ER+), locally advanced or metastatic breast cancer in postmenopausal women: not previously treated with endocrine therapy, or with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy FALCON
    Breast Cancer
    		 Breast Cancer ER+ FALCON

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Alpelisib Fulvestrant Placebo + fulvestrant Treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, locally advanced or MBC with a PIK3CA mutation after disease progression following ET as monotherapy SOLAR-1
    Breast Cancer
    		 Breast Cancer PIK3CA-mutated HR+ HER2- SOLAR-1

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Trastuzumab deruxtecan - Single arm HER2-positive breast cancer that is metastatic (has spread to other parts of the body) or cannot be removed by surgery. HER2-positive means that the cancer cells produce a protein called HER2 in large quantities on their surface, which makes the tumour cells grow more quickly. Used on its own in patients who have received one or more HER2-targeted treatments DESTINY-Breast01
    Breast Cancer
    		 Breast Cancer HER2+ DESTINY-Breast01

    2

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      2
    Talazoparib - Standard chemotherapy Treatment of patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or MBC who have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless unsuitable for these treatments EMBRACA
    Breast Cancer
    		 Breast Cancer HER2- g-BrCa+ve EMBRACA

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Olaparib - Standard chemotherapy Treatment of patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or MBC who have been previously treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless unsuitable for these treatments OlympiAD
    Breast Cancer
    		 Breast Cancer HER2- g-BrCa+ve OlympiAD

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Tucatinib Trastuzumab + capecitabine Placebo, trastuzumab + capecitabine HER2-positive locally advanced or metastatic breast cancer after at least 2 prior anti-HER2 treatment regimes HER2CLIMB
    Breast Cancer
    		 Breast Cancer HER2+ HER2CLIMB

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Binimetinib Encorafenib Vemurafenib In combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation COLUMBUS
    Skin Cancers
    		 Cutaneous Melanoma BRAF V600 COLUMBUS

    A

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a/F1
      5

      A
    Ramucirumab Erlotinib Placebo + Erlotinib First-line treatment of NSCLC with EGFR mutation RELAY
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ RELAY

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Durvalumab - Placebo Treatment of adult patients with unresectable, stage III NSCLC whose disease has not progressed following concurrent platinum-based CRT PACIFIC
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer PD-L1 PACIFIC

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Atezolizumab Nab-paclitaxel Placebo + nab-paclitaxel Treatment of patients with unresectable locally advanced or metastatic TNBC whose tumours have PD-L1 expression ≥1% and who have not received prior ChT for metastatic disease IMpassion130
    Breast Cancer
    		 Breast Cancer Triple-negative PD-L1+≥1% IMpassion130

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Dab/Tram (dabrafenib and trametinib) - Placebo In combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection COMBI-AD
    Skin Cancers
    		 Cutaneous Melanoma BRAF V600 COMBI-AD

    NEB

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1
      NEB
    Pembrolizumab - Placebo Adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB, IIC or III melanoma and who have undergone complete resection KEYNOTE-054
    Skin Cancers
    		 Cutaneous Melanoma - KEYNOTE-054

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.